These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 28390563)
1. Biomarkers for Adverse Pregnancy Outcomes in Rheumatic Diseases. Soh MC; Nelson-Piercy C Rheum Dis Clin North Am; 2017 May; 43(2):201-214. PubMed ID: 28390563 [TBL] [Abstract][Full Text] [Related]
2. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Kim MY; Buyon JP; Guerra MM; Rana S; Zhang D; Laskin CA; Petri M; Lockshin MD; Sammaritano LR; Branch DW; Porter TF; Merrill JT; Stephenson MD; Gao Q; Karumanchi SA; Salmon JE Am J Obstet Gynecol; 2016 Jan; 214(1):108.e1-108.e14. PubMed ID: 26432463 [TBL] [Abstract][Full Text] [Related]
3. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia. Turpin CA; Sakyi SA; Owiredu WK; Ephraim RK; Anto EO BMC Pregnancy Childbirth; 2015 Aug; 15():189. PubMed ID: 26303772 [TBL] [Abstract][Full Text] [Related]
4. Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. Conroy AL; McDonald CR; Gamble JL; Olwoch P; Natureeba P; Cohan D; Kamya MR; Havlir DV; Dorsey G; Kain KC Am J Obstet Gynecol; 2017 Dec; 217(6):684.e1-684.e17. PubMed ID: 29031892 [TBL] [Abstract][Full Text] [Related]
5. Angiogenic and fibrinolytic factors in blood during the first half of pregnancy and adverse pregnancy outcomes. Coolman M; Timmermans S; de Groot CJ; Russcher H; Lindemans J; Hofman A; Geurts-Moespot AJ; Sweep FC; Jaddoe VV; Steegers EA Obstet Gynecol; 2012 Jun; 119(6):1190-200. PubMed ID: 22617584 [TBL] [Abstract][Full Text] [Related]
6. Association of first-trimester angiogenic factors with placental histological findings in late-onset preeclampsia. Triunfo S; Crovetto F; Crispi F; Rodriguez-Sureda V; Dominguez C; Nadal A; Peguero A; Gratacos E; Figueras F Placenta; 2016 Jun; 42():44-50. PubMed ID: 27238713 [TBL] [Abstract][Full Text] [Related]
7. A placenta clinic approach to the diagnosis and management of fetal growth restriction. Kingdom JC; Audette MC; Hobson SR; Windrim RC; Morgen E Am J Obstet Gynecol; 2018 Feb; 218(2S):S803-S817. PubMed ID: 29254754 [TBL] [Abstract][Full Text] [Related]
8. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Rana S; Burke SD; Karumanchi SA Am J Obstet Gynecol; 2022 Feb; 226(2S):S1019-S1034. PubMed ID: 33096092 [TBL] [Abstract][Full Text] [Related]
9. In vivo uteroplacental release of placental growth factor and soluble Fms-like tyrosine kinase-1 in normal and preeclamptic pregnancies. Holme AM; Roland MC; Henriksen T; Michelsen TM Am J Obstet Gynecol; 2016 Dec; 215(6):782.e1-782.e9. PubMed ID: 27503620 [TBL] [Abstract][Full Text] [Related]
10. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Smith GC; Crossley JA; Aitken DA; Jenkins N; Lyall F; Cameron AD; Connor JM; Dobbie R Obstet Gynecol; 2007 Jun; 109(6):1316-24. PubMed ID: 17540803 [TBL] [Abstract][Full Text] [Related]
11. Angiogenic biomarkers in pregnancy: defining maternal and fetal health. Rasmussen LG; Lykke JA; Staff AC Acta Obstet Gynecol Scand; 2015 Aug; 94(8):820-32. PubMed ID: 25753566 [TBL] [Abstract][Full Text] [Related]
12. Prospective study of placental angiogenic factors and maternal vascular function before and after preeclampsia and gestational hypertension. Noori M; Donald AE; Angelakopoulou A; Hingorani AD; Williams DJ Circulation; 2010 Aug; 122(5):478-87. PubMed ID: 20644016 [TBL] [Abstract][Full Text] [Related]
13. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Baltajian K; Bajracharya S; Salahuddin S; Berg AH; Geahchan C; Wenger JB; Thadhani R; Karumanchi SA; Rana S Am J Obstet Gynecol; 2016 Jul; 215(1):89.e1-89.e10. PubMed ID: 26827880 [TBL] [Abstract][Full Text] [Related]
15. Angiogenic Markers and Cardiovascular Indices in the Prediction of Hypertensive Disorders of Pregnancy. Verlohren S; Perschel FH; Thilaganathan B; Dröge LA; Henrich W; Busjahn A; Khalil A Hypertension; 2017 Jun; 69(6):1192-1197. PubMed ID: 28461601 [TBL] [Abstract][Full Text] [Related]
16. Role of angiogenic factors in the pathogenesis and management of pre-eclampsia. Ngene NC; Moodley J Int J Gynaecol Obstet; 2018 Apr; 141(1):5-13. PubMed ID: 29222938 [TBL] [Abstract][Full Text] [Related]
17. Angiogenic factors in maternal circulation and preeclampsia with or without fetal growth restriction. Vatten LJ; Åsvold BO; Eskild A Acta Obstet Gynecol Scand; 2012 Dec; 91(12):1388-94. PubMed ID: 22882089 [TBL] [Abstract][Full Text] [Related]
18. Placental Growth Factor, Soluble fms-Like Tyrosine Kinase 1, Soluble Endoglin, IL-6, and IL-16 as Biomarkers in Preeclampsia. Rădulescu C; Bacârea A; Huțanu A; Gabor R; Dobreanu M Mediators Inflamm; 2016; 2016():3027363. PubMed ID: 27799724 [TBL] [Abstract][Full Text] [Related]
19. Circulating angiogenic factors in preeclampsia, gestational proteinuria, and preeclampsia superimposed on chronic glomerulonephritis. Masuyama H; Suwaki N; Nakatsukasa H; Masumoto A; Tateishi Y; Hiramatrsu Y Am J Obstet Gynecol; 2006 Feb; 194(2):551-6. PubMed ID: 16458660 [TBL] [Abstract][Full Text] [Related]